Aussie Government, CSL Called Too Close For Good Vaccine Policy
This article was originally published in PharmAsia News
The Australian government and CSL may have been too cozy to see some of the problems involved with the company's flu vaccine, a rival researcher says
You may also be interested in...
The international group of pharmaceutical inspectorates, PIC/S, has issued an aide-memoire and a Q&A document to support its 2018 guideline on using health-based exposure limits to assess the risk of cross contamination in shared manufacturing facilities.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Sanofi's Sarclisa for treating adults with relapsed and refractory multiple myeloma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
Progress for two US-based companies in the race to develop a COVID-19 vaccine.